Monitor the December 2026 safety data readout for MP0712 and any subsequent financing events. The going concern disclosure and inability to raise capital since 2024 make the company dependent on either a successful capital raise or positive clinical catalysts to extend runway beyond late 2027.
Price Chart
Executive Summary
Molecular Partners reported Q3 2026 results with no revenue and a net loss of CHF 11.7M ($0.31 per share), slightly narrower than the year-ago loss of CHF 11.8M ($0.33 per share). The company announced a strategic pivot to radiopharmaceuticals and a workforce reduction of up to 44% (55 positions), while disclosing a material uncertainty about its ability to continue as a going concern due to insufficient cash runway beyond late 2027 and inability to raise new funding since October 2024.
Key Financial Metrics
Key Facts
- No revenue reported for Q3 2026 or Q3 2025; the company is pre-revenue
- Net loss for Q3 2026 was CHF 11.7M ($0.31 per share) vs CHF 11.8M ($0.33 per share) in Q3 2025
- Cash and cash equivalents of CHF 57.5M ($69M) as of September 30, 2026, expected to fund operations into late 2027
- Company disclosed material uncertainty about going concern, citing inability to obtain additional funding since October 2024
- Workforce reduction of up to 55 positions (44% of workforce) announced as part of restructuring to focus on radiopharmaceuticals
- Full year 2026 operating expense guidance updated to CHF 50-55M
- Lead asset MP0712 (DLL3-targeting Radio-DARPin) Phase 1/2a study ongoing; initial safety data expected December 2026, efficacy data in 2027
Financial Impact
Cash burn of CHF 25.2M in 9M 2026; cash runway into late 2027; restructuring costs not yet estimable
Risk Factors
- Going concern risk: material uncertainty about ability to continue as a going concern due to inability to raise funds since October 2024
- Cash runway only into late 2027; no revenue and no near-term path to profitability
- Workforce reduction of 44% may impair R&D execution and pipeline advancement
- Clinical-stage biotech with no approved products; lead asset MP0712 efficacy data not expected until 2027
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001745114-26-000033 |
| Document: pr_molecularpartnersxq3202.htm | 0001745114-26-000033 |
| Document: 0001745114-26-000033-index-headers.html | 0001745114-26-000033 |
| Document: 0001745114-26-000033-index.html | 0001745114-26-000033 |
| Document: 0001745114-26-000033.txt | 0001745114-26-000033 |
| Earnings Context (Synthetic; results releases only) | 0001745114-26-000033 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 29, 2026 3d ago | 6-K | No price | awaiting T+20 | awaiting T+20 | No price |
Oct 29, 2026 3d ago | Press Release | $3.53 | awaiting T+20 | awaiting T+20 | $3.58 (+1.42%) |
Aug 25, 2026 9w ago | 6-K | $4.38 $3.99 | ▼ −8.90% | ▼ −10.15% | $3.58 (−18.26%) |
Jul 20, 2026 14w ago | 6-K | $4.00 $4.25 | ▲ +6.25% | ▲ +2.13% | $3.58 (−10.50%) |
Jul 16, 2026 15w ago | Press Release | $4.10 $4.21 | ▲ +2.68% | ▼ −0.93% | $3.58 (−12.68%) |
Jul 6, 2026 16w ago | Press Release | $4.00 $3.93 | ▼ −1.75% | ▼ −1.18% | $3.58 (−10.50%) |
Jul 2, 2026 17w ago | 6-K | $3.98 $3.93 | ▼ −1.26% | ▼ −0.84% | $3.58 (−10.05%) |
Jul 2, 2026 17w ago | Press Release | $3.98 $3.93 | ▼ −1.26% | ▼ −0.84% | $3.58 (−10.05%) |
Jun 1, 2026 21w ago | 6-K | $3.95 $3.87 | ▼ −2.03% | ▼ −0.73% | $3.58 (−9.37%) |
May 12, 2026 24w ago | 6-K | $4.00 $3.71 | ▼ −7.25% | ▼ −6.64% | $3.58 (−10.50%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers